Every 10-Q that Acrivon Therapeutics, Inc. (ACRV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACRV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRV filings page.
Acrivon Therapeutics, Inc. is a clinical-stage oncology company using its AP3 (Acrivon Predictive Precision Proteomics) platform to design and develop precision medicines. The lead asset ACR-368 (CHK1/2 inhibitor) is in a registrational-intent Phase 2b trial in endometrial cancer, guided by the protein-based OncoSignature assay and combinations such as ultra-low dose gemcitabine. Interim data cited include an overall response rate of 39% in OncoSignature-positive endometrial cancer Arm 1 and 52% in pooled serous endometrial cancer patients with ≤2 prior lines of therapy.
The second asset ACR-2316, a dual WEE1/PKMYT1 inhibitor, has advanced into randomized dose-expansion Phase 1/2 cohorts, while internally discovered CDK11 inhibitors remain in preclinical development. For the quarter ended June 30, 2026, Acrivon reported R&D expenses of $13.8 million and G&A expenses of $4.8 million, with a quarterly net loss of $18.0 million and a six‑month net loss of $37.0 million. Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026, after raising about $7.3 million via an at-the-market stock offering at $1.80 per share. The company states this liquidity is expected to fund operations into the fourth quarter of 2027. As of August 7, 2026, there were 42.9 million common shares outstanding.
Acrivon Therapeutics reported a net loss of $19.0 million for the quarter ended March 31, 2026, slightly improved from $19.7 million a year earlier. Research and development expenses were $15.2 million, reflecting continued investment in lead programs ACR-368 and ACR-2316, while general and administrative costs declined to $4.7 million as stock-based compensation decreased.
Cash, cash equivalents and investments totaled $97.7 million at quarter-end, and the company subsequently raised an additional $7.3 million through its at-the-market equity program. Management believes this liquidity will fund operations into the third quarter of 2027 as it advances its precision oncology pipeline, including a registrational-intent Phase 2b trial of ACR-368 in endometrial cancer and a Phase 1/2 trial of WEE1/PKMYT1 inhibitor ACR-2316.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of $18.2 million for the quarter, improving from $22.4 million a year ago, as research and development expense decreased to $13.6 million (from $18.9 million). General and administrative expense was $6.0 million. Basic and diluted net loss per share was $0.47.
For the nine months ended September 30, net loss was $58.9 million, with operating cash use of $48.4 million. Acrivon ended the quarter with cash, cash equivalents and investments of $134.4 million, which management states is sufficient for at least 12 months and supports a projected runway into the second quarter of 2027.
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of November 7, 2025, shares outstanding were 31,555,126.
Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.
Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.